Search results
Exclusive: SR One raises $200M+ for third fund, still with GSK support
Endpoints News· 5 days agoSR One, a life sciences venture capital firm that years ago split from GSK, has raised more than...
GSK's experimental drug shows promise in reducing severe asthma attacks
AOL· 7 days agoThe drug, called depemokimab, showed "significant and meaningful reductions" in asthma attacks for patients with eosinophilic asthma, GSK said on Tuesday. This form of asthma ...
3 Top Dividend Stocks to Maximize Your Retirement Income
Zacks via Yahoo Finance· 15 hours agoThe traditional retirement planning approaches no longer cover all expenses in nest egg years. So...
Zantac not a cause of woman’s cancer, jury says in first trial over drug
Reuters via Yahoo News· 4 days agoThe jury in Cook County, Illinois circuit court agreed with arguments from drugmakers GSK and...
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks· 4 days agoTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
GSK's SWIFT trial anthology shows long-acting treatment reduces asthma attacks
FierceBiotech· 7 days agoIt’s not a double album release, but it’s a close runner-up: The pivotal SWIFT-1 and SWIFT-2 trials have shown that GSK's long-acting asthma treatment reduces attacks. Center ...
GSK Sees Positive Results for Severe Asthma Treatment Depemokimab
Market Watch· 7 days agoBy Najat Kantouar GSK said that it had positive results from phase III trials of depemokimab, aimed at assessing the drug's efficacy and safety in adults and...
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks via Yahoo Finance· 4 days agoUtilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies...
Zantac not a cause of woman’s cancer, jury says in first trial over drug
Reuters via AOL· 4 days agoThe jury in Cook County, Illinois circuit court agreed with arguments from drugmakers GSK and...
GSK finds success in severe asthma drug trials
Becker’s Hospital Review· 7 days agoAfter positive results in phase 3 trials, a GSK experimental therapy could be the first ultra-long-acting biologic approved for severe asthma. The drug candidate, depemokimab ...
